Rhein Minapharm Biogenetics signed a joint research agreement with Rephartox to develop three new vaccine formulations.
Both Rhein Minapharm and Rephartox have also set the framework for future cooperation in other research areas of common interest.
"Our goal is to be the leading innovator in the field of Biotechnology in the Middle East Region"
said Dr. Amr EL Chabrawichi, chairman of the board of Rhein Minapharm, on this occasion. |
Standing from left to right: Dr.Chabrawichi,CEO, Rhein Minapharm, Dr.Ben Rademaker, CEO of Rephartox
|
